【2017】鸡年交易记录

yourock

dragonballz 发表于 2017-9-11 15:43
If there is really a bidding between multiple bidders, including A2 milk, the return of MGC would  ...

难道你们投资股票都是这么赌消息的？

yourock

感觉黄金也许开始回调了。

bondzh

yourock 发表于 2017-9-11 22:39
感觉黄金也许开始回调了。

回调已经开始了，第一目标位1320。昨天rsg的挂单取消，继续等企稳。长线看涨不变

dragonballz

yourock 发表于 2017-9-11 22:33
难道你们投资股票都是这么赌消息的？

Not really betting on the rumors. I works with a nurse whose family is 4 generation diary farmers belongs to MGC. They are circulating those intentions from company management already.

dragonballz

bondzh 发表于 2017-9-12 07:17
回调已经开始了，第一目标位1320。昨天rsg的挂单取消，继续等企稳。长线看涨不变 ...

Wait for US congress discussion about tougher sanction on NK and Sanpang's fight-back

dragonballz

Phew, I will hold BMY bit longer now. Setting up from US$49 last August finally paid back

Australian cancer research institutes also run a trial of BMY's Opdivo-Yervoy combination to treat late stages melanoma at present. Hopefully it would be proved positive as well.
===========

Bristol-Myers Squibb smashed doubt about Opdivo and Yervoy’s utility in first-line kidney cancer on Sunday with data showing patients lived longer when treated up front with the combo, rather than with Pfizer’s standard-of-care med, Sutent.

The fleshed-out data followed closely on a surprise stop for the Checkmate-214 trial after an interim analysis, when a monitoring committee decided the Opdivo-Yervoy combo was too effective to restrict only to the control arm in the study.

In essence, Opdivo and Yervoy may not have hit their goal of delaying cancer growth, but did show they could help patients live longer, which is the gold-standard endpoint in cancer. That means Bristol-Myers could file for a full FDA approval for first-line treatment of renal cell carcinoma—another example of IO drugmakers’ push into earlier use of their therapies.

========

Now eyes on FDA approving the combo or not. If approved, potential huge booster for BMY's share priceOL

maybeming

dragonballz 发表于 2017-9-12 08:58
Phew, I will hold BMY bit longer now. Setting up from US$49 last August finally paid back

Austral ...

is this a one trick pony or diversified player like CSL?

dragonballz

maybeming 发表于 2017-9-12 09:19
is this a one trick pony or diversified player like CSL?

It is double or triple the size of CSL. A big fish in pharmaceutical sector
not a black horse at all but just bit unlucky in 2016.

maybeming

dragonballz 发表于 2017-9-12 09:30
It is double or triple the size of CSL. A big fish in pharmaceutical sector
not a black horse ...

Nice! enjoy the ride

maybeming

yourock 发表于 2017-9-11 22:39
感觉黄金也许开始回调了。

目测RSG又是最惨的

Coolbananas

maybeming 发表于 2017-9-12 09:39
目测RSG又是最惨的

我觉得ogc 会更惨，虽然hold 一点点损失不大，但是还是觉得上周没放掉可惜了。

MXST18

昨晚怎么了？美股涨那么凶

tiansen90904

问个傻问题，RSG在8点前就有377,600的交易量了，这是为什么？而且这个交易的condition显示LT XT，这是代表什么意思？

yourock

maybeming 发表于 2017-9-12 09:39
目测RSG又是最惨的

Rsg重心一直在下移 趋势并没有改变。现在这个金价 rsg已经又奔1.1去了。如果金价调整1300 这股会去探1块。

dragonballz

maybeming 发表于 2017-9-12 09:32
Nice! enjoy the ride

Typically pharmaceutical companies (excluding generic companies like MYX/Teva) put huge amount of money into researching. Once they break through or achieve revolutionary drug, it would boost huge gains. Lipitor to Pfizer/Sovaldi to Gilead are good examples. Sovaldi was once labelled as the most expensive drug ever in the market.

the other good benefit to buy them is most of good pharmaceutical companies hold large amount of cash at hand. Gilead one stage held about US$100bn and did not know where to spend them till last month it bought a small cancer drug company, which also boostered its price from 6x to 80 within a month.

Disadvantage is risk of tumbling. If their star drug fails or patent expired, they suddenly lost attraction and price would have a free fall. BMY had trouble with its Opdivo last year for treatment towards lung cancer so that its price fell from $90 straight to $50 within a month. So buy dip would work for those companies as they won't be bankruptcy as good cash at hand

maybeming

31 sold NAB

bondzh

bondzh 发表于 2017-9-7 10:13
目前看，与预期一致，昨天只是假突破。回调到1.2守住了就可以加仓了。1.2守不住的话，1.15强支持。长线看 ...

看起来是去1.15了。

bondzh

bondzh 发表于 2017-9-11 13:09
我5.79也空起来了，止损今日高点，先看到5.4附近

今天止损出局，回到盘整区间，假突破

alix

mark

SilverRanger

SLR/RSG 对冲终于...:

dragonballz

bondzh 发表于 2017-9-12 10:26
今天止损出局，回到盘整区间，假突破

You are back to be active now. Good for us.

Could you please have a look at Gilead's trending again? Any potential to be back to record high, $120?

maybeming

mqg...这是突破了吗，要不要追一波

bondzh

dragonballz 发表于 2017-9-12 11:16
You are back to be active now. Good for us.

Could you please have a look at Gilead's trending aga ...

突破长期下降趋势线了，反转，有可能去120，但现在已经到周线级别强阻力位了，估计要回调，76附近能回踩是很好的补仓位，下一个阻力在103

dragonballz

bondzh 发表于 2017-9-12 11:49
突破长期下降趋势线了，反转，有可能去120，但现在已经到周线级别强阻力位了，估计要回调，76附近能回踩 ...

I will keep a close eye on it. As a fundamental analysis, Gilead has an undisputable advantage in antiviral medications (Hep C/HIV) and recently purchased a small company with capacity of cancer drug; therefore, it marches into another thriving sector with huge growth potentials. Definitely it worth buying at your recommend price. $76, here I go.

dragonballz

dragonballz 发表于 2017-9-12 08:58
Phew, I will hold BMY bit longer now. Setting up from US$49 last August finally paid back

Austral ...

Astina translated the news about Australian trial of melanoma treatment. very promising at present

link: http://www.oursteps.com.au/bbs/f ... &extra=page%3D1

bondzh

maybeming 发表于 2017-9-12 11:32
mqg...这是突破了吗，要不要追一波

昨天回84以上可以考虑，今天就迟了，asx离5800不远了，到时候还会跌回来

bondzh

dragonballz 发表于 2017-9-12 11:16
You are back to be active now. Good for us.

Could you please have a look at Gilead's trending aga ...

忘了说了：I am back!

dragonballz

bondzh 发表于 2017-9-12 12:03
忘了说了：I am back!

Hast la vista. Arnold Schwarzenger always said that

maybeming

dragonballz 发表于 2017-9-12 12:19
Hast la vista. Arnold Schwarzenger always said that

rmd is on fire too,any price target to sell?

bondzh

Bhp27.25空，止损设27.33。目标昨日低点，下破继续持有